Treatment of peritoneal carcinomatosis using carboplatin-loaded hydroxyapatite particles
Hiromitsu Takeyama1, Noriaki Mohri, Isamu Mizuno
1Department of Gastroenterological Surgery, Nagoya City University, Graduate School of Medical Sciences, Kawasumi-1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. takeyama@med.nagoya-cu.ac.jp
Unlabelled:
The anti-tumor effects and tissue distribution of carboplatin (CBDCA) incorporated into hydroxyapatite (HAP) particles was studied.
Materials And Methods:
Seven days after the intraperitoneal (i.p.) implantation of AH130 tumor cells into Donryu rats, the animals were randomized into four groups: group I was treated with saline i.p.; Group II, with CBDCA i.v.; group III with CBDCA i.p.; and group IV with HAP-CBDCA i.p.
Results:
The survival rate of group IV was better than that of the other groups (p < 0.05). The area under the ascitic platinum concentration-time curve and tissue concentrations of platinum in the omentum after 24 hours of treatment were higher in group IV than in groups II or III (p < 0.05). The platinum concentrations in the kidneys of group IV were lower than in group III (p < 0.05).
Conclusion:
The HAP-CBDCA combination enhances the anti-tumor effects of the drug and reduces the nephrotoxicity in rats with peritoneal carcinomatosis.
More Related Videos
09:02Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
